These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 18056200)

  • 1. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
    Jain HV; Meyer-Hermann M
    Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
    Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
    Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
    Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
    Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
    Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.
    Dodier P; Piché A
    Gynecol Oncol; 2006 Feb; 100(2):254-63. PubMed ID: 16188300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
    Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
    Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
    Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
    Tagscherer KE; Fassl A; Sinkovic T; Combs SE; Roth W
    Apoptosis; 2012 Feb; 17(2):187-99. PubMed ID: 22002102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.